| Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule J Baselga, X Carbonell, NJ Castañeda-Soto, M Clemens, M Green, ... Journal of Clinical Oncology 23 (10), 2162-2171, 2005 | 557 | 2005 |
| Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials PS Sanmuganathan, P Ghahramani, PR Jackson, EJ Wallis, LE Ramsay Heart 85 (3), 265-271, 2001 | 543 | 2001 |
| Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens L Purkins, N Wood, P Ghahramani, K Greenhalgh, MJ Allen, ... Antimicrobial agents and chemotherapy 46 (8), 2546-2553, 2002 | 495 | 2002 |
| Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer U Gatzemeier, G Groth, C Butts, N Van Zandwijk, F Shepherd, A Ardizzoni, ... Annals of oncology 15 (1), 19-27, 2004 | 459 | 2004 |
| Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel B Leyland-Jones, K Gelmon, JP Ayoub, A Arnold, S Verma, R Dias, ... Journal of Clinical Oncology 21 (21), 3965-3971, 2003 | 375 | 2003 |
| Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population EJ Wallis, LE Ramsay, IUI Haq, P Ghahramani, PR Jackson, KR Yeo, ... Bmj 320 (7236), 671-676, 2000 | 268 | 2000 |
| Translational medicine definition by the European Society for Translational Medicine RJ Cohrs, T Martin, P Ghahramani, L Bidaut, PJ Higgins, A Shahzad New Horizons in Translational Medicine 2 (3), 86-88, 2015 | 240 | 2015 |
| Association of panic disorder and panic attacks with hypertension SJC Davies, P Ghahramani, PR Jackson, TW Noble, PG Hardy, ... The American journal of medicine 107 (4), 310-316, 1999 | 187 | 1999 |
| Clinical relevance of dissolution testing in quality by design PA Dickinson, WW Lee, PW Stott, AI Townsend, JP Smart, P Ghahramani, ... The AAPS journal 10, 380-390, 2008 | 168 | 2008 |
| Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration L Purkins, N Wood, P Ghahramani, ER Love, MD Eve, A Fielding British journal of clinical pharmacology 56, 37-44, 2003 | 143 | 2003 |
| Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO RR Girgis, M Slifstein, D D’Souza, Y Lee, A Periclou, P Ghahramani, ... Psychopharmacology 233, 3503-3512, 2016 | 123 | 2016 |
| Influence of genetic polymorphisms in the β2-adrenoceptor on desensitization in human lung mast cells LK Chong, J Chowdry, P Ghahramani, PT Peachell Pharmacogenetics and Genomics 10 (2), 153-162, 2000 | 104 | 2000 |
| Cytochromes P450 mediating the N‐demethylation of amitriptyline P Ghahramani, SW Ellis, MS Lennard, LE Ramsay, GT Tucker British journal of clinical pharmacology 43 (2), 137-144, 1997 | 102 | 1997 |
| Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus J Chalmers Journal of Hypertension, Supplement 19 (S4), S21-S28, 2001 | 85 | 2001 |
| Panic disorder, anxiety and depression in resistant hypertension-a case–control study SJC Davies, P Ghahramani, PR Jackson, J Hippisley-Cox, WW Yeo, ... Journal of hypertension 15 (10), 1077-1082, 1997 | 82 | 1997 |
| Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients SJC Davies, PR Jackson, LE Ramsay, P Ghahramani Archives of internal medicine 163 (5), 592-600, 2003 | 72 | 2003 |
| PRN prescribing in psychiatric inpatients–potential for pharmacokinetic drug interactions SJC Davies, MS Lennard, P Ghahramani, P Pratt, A Robertson, J Potokar Journal of Psychopharmacology 21 (2), 153-160, 2007 | 53 | 2007 |
| Quantitative analysis of amitriptyline and nortriptyline in human plasma and liver microsomal preparations by high-performance liquid chromatography P Ghahramani, MS Lennard Journal of Chromatography B: Biomedical Sciences and Applications 685 (2 …, 1996 | 53 | 1996 |
| Protection by dexamethasone of the functional desensitization to β2‐adrenoceptor‐mediated responses in human lung mast cells LK Chong, DEJ Drury, JF Dummer, P Ghahramani, RP Schleimer, ... British journal of pharmacology 121 (4), 717-722, 1997 | 52 | 1997 |
| Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants L Chen, R Boinpally, WM Greenberg, J Wangsa, A Periclou, ... Clinical drug investigation 34, 351-359, 2014 | 51 | 2014 |
